Znanstveni rad - Izvorni znanstveni rad
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

Reches, Adi; Ophir, Yael; Stein, Natan; Kol, Inbal; Isaacson, Batya; Charpak Amikam, Yoav; Elnekave, Afek; Tsukerman, Pinchas; Kučan Brlić, Paola; Lenac, Tihana; Seliger, Barbara; Jonjić, Stipan; Mandelboim, Ofer (2020)

Citirajte ovaj rad

Reches, A., Ophir, Y., Stein, N., Kol, I., Isaacson, B., Charpak Amikam, Y. ... Mandelboim, O. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer, 8. (1). doi: 10.1136/jitc-2019-000266

Reches, Adi, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer, vol. 8, br. 1, 2020. https://doi.org/10.1136/jitc-2019-000266

Reches, Adi, Yael Ophir, Natan Stein, Inbal Kol, Batya Isaacson, Yoav Charpak Amikam, Afek Elnekave, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer 8, br. 1 (2020). https://doi.org/10.1136/jitc-2019-000266

Reches, A., et al. (2020) 'Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity', Journal for ImmunoTherapy of Cancer, 8(1). doi: 10.1136/jitc-2019-000266

Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, i sur.. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer [Internet]. 06.2020. [pristupljeno 12.07.2020.];8(1). doi: 10.1136/jitc-2019-000266

A. Reches, et al., "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity", Journal for ImmunoTherapy of Cancer, vol. 8, br. 1, Lipanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:706583. [Citirano: 12.07.2020.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.